Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity
Eros Di Giorgio, … , Ulf H. Beier, Wayne W. Hancock
Eros Di Giorgio, … , Ulf H. Beier, Wayne W. Hancock
Published August 13, 2020
Citation Information: J Clin Invest. 2020;130(12):6242-6260. https://doi.org/10.1172/JCI135486.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 6

MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity

  • Text
  • PDF
Abstract

The transcription factor MEF2D is important in the regulation of differentiation and adaptive responses in many cell types. We found that among T cells, MEF2D gained new functions in Foxp3+ T regulatory (Treg) cells due to its interactions with the transcription factor Foxp3 and its release from canonical partners, like histone/protein deacetylases. Though not necessary for the generation and maintenance of Tregs, MEF2D was required for the expression of IL-10, CTLA4, and Icos, and for the acquisition of an effector Treg phenotype. At these loci, MEF2D acted both synergistically and additively to Foxp3, and downstream of Blimp1. Mice with the conditional deletion in Tregs of the gene encoding MEF2D were unable to maintain long-term allograft survival despite costimulation blockade, had enhanced antitumor immunity in syngeneic models, but displayed only minor evidence of autoimmunity when maintained under normal conditions. The role played by MEF2D in sustaining effector Foxp3+ Treg functions without abrogating their basal actions suggests its suitability for drug discovery efforts in cancer therapy.

Authors

Eros Di Giorgio, Liqing Wang, Yan Xiong, Tatiana Akimova, Lanette M. Christensen, Rongxiang Han, Arabinda Samanta, Matteo Trevisanut, Tricia R. Bhatti, Ulf H. Beier, Wayne W. Hancock

×

Total citations by year

Year: 2024 2023 2021 Total
Citations: 7 2 6 15
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (15)

Title and authors Publication Year
Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers
Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M
2024
The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases.
Sumida TS, Cheru NT, Hafler DA
Nature reviews. Immunology 2024
Foxp3 depends on Ikaros for control of regulatory T cell gene expression and function
Thomas RM, Pahl MC, Wang L, Grant SF, Hancock WW, Wells AD
eLife 2024
HDAC4 influences the DNA damage response and counteracts senescence by assembling with HDAC1/HDAC2 to control H2BK120 acetylation and homology-directed repair
Di Giorgio E, Dalla E, Tolotto V, D\u2019Este F, Paluvai H, Ranzino L, Brancolini C
Nucleic Acids Research 2024
The Molecular and Biological Function of MEF2D in Leukemia.
Zhang P, Lu R
Advances in experimental medicine and biology 2024
T-regulatory cells require Sin3a for stable expression of Foxp3
Christensen LM, Akimova T, Wang L, Han R, Samanta A, Di Giorgio E, Hancock WW
Frontiers in Immunology 2024
The universal role of adaptive transcription in health and disease.
Lissek T
The FEBS journal 2024
A ubiquitin-dependent switch on MEF2D senses the pro-metastatic niche signals to facilitate intrahepatic metastasis of liver cancer
Junyu Xiang, Ni Zhang, Meng Liu, Jinyang Li, Luming Yang, Xue Bai, Xianfeng Li, Aibei Du, Lin Wang, Qin Liu, Tao Wang, Liangzhi Wen, Dongfeng Chen, Li Su, Bin Wang
Advanced Science 2023
The transcription factor Mef2d regulates B:T synapse-dependent GC-Tfh differentiation and IL-21-mediated humoral immunity
Kim YJ, Oh J, Jung S, Kim CJ, Choi J, Jeon YK, Kim HJ, Kim JW, Suh CH, Lee Y, Im SH, Crotty S, Choi YS
Science Immunology 2023
Mechanisms of exTreg induction
V Saxena, R Lakhan, J Iyyathurai, JS Bromberg
European Journal of Immunology 2021
Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9
C Brancolini, ED Giorgio, L Formisano, T Gagliano
Life Sciences 2021
A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells
ED Giorgio, L Wang, Y Xiong, LM Christensen, T Akimova, R Han, A Samanta, M Trevisanut, C Brancolini, UH Beier, WW Hancock
Frontiers in immunology 2021
SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators
X Ma, A Somasundaram, Z Qi, DJ Hartman, H Singh, HU Osmanbeyoglu
Nucleic Acids Research 2021
Editorial: CD4+ T Cells in Cancer Immunotherapies
JM González-Navajas, E Elkord, J Lee
Frontiers in immunology 2021
Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
L Zhao, P Zhang, P Galbo, X Zhou, S Aryal, S Qiu, H Zhang, Y Zhou, C Li, D Zheng, R Bhatia, R Lu
Blood Advances 2021

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 5 X users
Referenced in 1 patents
33 readers on Mendeley
See more details